Apple lower as analyst points to indications of less-than-expected demand for iPhone 16 Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- NuCana (NCNA) up 149% after presenting final data from the Phase 2 NuTide:701 study at ESMO
- Zentalis (ZNTL) up 40% after the FDA lifted the partial clinical hold on studies of azenosertib
- Bausch + Lomb (BLCO) up 17% after Financial Times reported Bausch + Lomb is considering a sale as a strategy to disentangle itself from its parent company
- Nuvalent (NUVL) up 21% after the company provided development updates for zidesamtinib and NVL-655
- Ascendis Pharma (ASND) up 18% after announcing topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP
UP AFTER EARNINGS -
DOWN AFTER EARNINGS -
LOWER -
- iTeos Therapeutics (ITOS) down 13% after reporting follow-up interim data from GALAXIES Lung-201
- Upstart (UPST) down 8% after announcing offering of $300M of Convertible Senior Notes due 2029
- Apple (AAPL) down 2% after analyst Ming Chi-Kuo noted Apple is seeing less demand for iPhone 16 Pro and iPhone 16 Pro Max than expected
Symbols:
BLCO NCNA ZNTL NUVL ASND MODV ALOT AAPL ITOS - $17.87 /
+0.9798 (+5.80%)
UPST Keywords: Fly Intel, Wall Street, Top Stories, Stocks
